OptimizeRx Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting net income of $1.195 million for the third quarter and essentially breakeven results for the nine months year-to-date.

Key Highlights

  • Q3 2026 net revenue: $21,615 thousand, compared with $26,067 thousand in Q3 2025, according to the filing.
  • Q3 2026 net income: $1,195 thousand ($0.06 per basic and diluted share), versus $779 thousand in Q3 2025.
  • Nine-month net loss: $(3) thousand for the nine months ended September 30, 2026, compared with net income of $112 thousand in the same period of 2025.
  • Total assets: $162,093 thousand at September 30, 2026, down from $176,918 thousand at December 31, 2025.
  • Long-term debt reduced: Long-term debt, net, fell to $11,479 thousand from $21,421 thousand at year-end 2025.
  • Shares outstanding: 18,906,823 common shares as of October 29, 2026.
  • Accumulated deficit: $(79,239) thousand at September 30, 2026, essentially flat versus $(79,236) thousand at December 31, 2025.

OptimizeRx Third-Quarter 2026 Financial Results and Balance Sheet Position

According to the filing, OptimizeRx Corporation (NASDAQ:OPRX) reported net revenue of $21,615 thousand for the three months ended September 30, 2026, a decrease from $26,067 thousand in the comparable prior-year quarter. Total expenses for Q3 2026 were $18,945 thousand, resulting in income from operations of $2,670 thousand. After net other expenses of $104 thousand, income before provision for income taxes was $2,566 thousand. An income tax expense of $1,371 thousand yielded net income of $1,195 thousand for the quarter.

For the nine months ended September 30, 2026, the registrant reported net revenue of $61,963 thousand versus $77,190 thousand in the same period of 2025. Total expenses for the nine-month period were $58,985 thousand, producing income from operations of $2,978 thousand. Interest expense of $2,459 thousand contributed to total other expenses, net of $2,152 thousand, resulting in income before taxes of $826 thousand. After an income tax expense of $829 thousand, the nine-month net loss was $(3) thousand, the filing disclosed.

On the balance sheet as of September 30, 2026, the company reported total assets of $162,093 thousand, with goodwill of $70,869 thousand and cash and cash equivalents of $22,325 thousand. Total liabilities decreased to $28,215 thousand from $48,624 thousand at December 31, 2025, reflecting a reduction in long-term debt. Total stockholders' equity rose to $133,878 thousand from $128,294 thousand at year-end 2025. The registrant is classified as a non-accelerated filer and smaller reporting company, and indicated it is not a shell company.

What Was Disclosed

OptimizeRx filed a quarterly report covering the period ended September 30, 2026, disclosing Q3 net income of $1,195 thousand on revenue of $21,615 thousand, a significantly reduced long-term debt balance, and total stockholders' equity of $133,878 thousand.